Literature DB >> 23318906

Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1.

Hitesh K Agarwal1, Craig A McElroy, Elena Sjuvarsson, Staffan Eriksson, Michael V Darby, Werner Tjarks.   

Abstract

Four different libraries of overall twenty three N3-substituted thymidine (dThd) analogues, including eleven 3-carboranyl thymidine analogues (3CTAs), were synthesized. The latter are potential agents for Boron Neutron Capture Therapy (BNCT) of cancer. Linker between the dThd scaffold and the m-carborane cluster at the N3-position of the 3CTAs contained amidinyl-(3e and 3f), guanidyl-(7e-7g), tetrazolylmethyl-(9b1/2-9d1/2), or tetrazolyl groups (11b1/2-11d1/2) to improve human thymidine kinase 1 (hTK1) substrate characteristics and water solubilities compared with 1st generation 3CTAs, such as N5 and N5-2OH. The amidinyl- and guanidyl-type N3-substitued dThd analogues (3a-3f and 7a-7g) had hTK1 phosphorylation rates of <30% relative to that of dThd, the endogenous hTK1 substrate, whereas the tetrazolyl-type N3-substitued dThd analogues (9a, 9b1/2-9d1/2 and 11a, 11b1/2-11d1/2) had relative phosphorylation rates (rPRs) of >40%. Compounds 9a, 9b1/2-9d1/2 and 11a, 11b1/2-11d1/2 were subjected to in-depth enzyme kinetics studies and the obtained rk(cat)/K(m) (k(cat)/K(m) relative to that of dThd) ranged from 2.5 to 26%. The tetrazolyl-type N3-substitued dThd analogues 9b1/2 and 11d1/2 were the best substrates of hTK1 with rPRs of 52.4% and 42.5% and rk(cat)/K(m) values of 14.9% and 19.7% respectively. In comparison, the rPR and rk(cat)/K(m) values of N5-2OH in this specific study were 41.5% and 10.8%, respectively. Compounds 3e and 3f were >1900 and >1500 times, respectively, better soluble in PBS (pH 7.4) than N5-2OH whereas solubilities for 9b1/2-9d1/2 and 11b1/2-11d1/2 were only 1.3-13 times better.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23318906      PMCID: PMC3587680          DOI: 10.1016/j.ejmech.2012.11.041

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  26 in total

1.  Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.

Authors:  Rohit Tiwari; Antonio Toppino; Hitesh K Agarwal; Tianyao Huo; Youngjoo Byun; Judith Gallucci; Sherifa Hasabelnaby; Ahmed Khalil; Ayman Goudah; Robert A Baiocchi; Michael V Darby; Rolf F Barth; Werner Tjarks
Journal:  Inorg Chem       Date:  2011-12-16       Impact factor: 5.165

2.  Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer.

Authors:  Sureshbabu Narayanasamy; B T S Thirumamagal; Jayaseharan Johnsamuel; Youngjoo Byun; Ashraf S Al-Madhoun; Elena Usova; Guirec Y Cosquer; Junhua Yan; Achintya K Bandyopadhyaya; Rohit Tiwari; Staffan Eriksson; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2006-07-10       Impact factor: 3.641

3.  Structure of a type II thymidine kinase with bound dTTP.

Authors:  Markus S Birringer; Michael T Claus; Gerd Folkers; Daniel P Kloer; Georg E Schulz; Leonardo Scapozza
Journal:  FEBS Lett       Date:  2005-02-28       Impact factor: 4.124

4.  Binding of ATP to TK1-like enzymes is associated with a conformational change in the quaternary structure.

Authors:  Dario Segura-Peña; Stefan Lutz; Christian Monnerjahn; Manfred Konrad; Arnon Lavie
Journal:  J Mol Biol       Date:  2007-03-15       Impact factor: 5.469

5.  Improved nucleotide selectivity and termination of 3'-OH unblocked reversible terminators by molecular tuning of 2-nitrobenzyl alkylated HOMedU triphosphates.

Authors:  Vladislav A Litosh; Weidong Wu; Brian P Stupi; Jinchun Wang; Sidney E Morris; Megan N Hersh; Michael L Metzker
Journal:  Nucleic Acids Res       Date:  2011-01-11       Impact factor: 16.971

6.  Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates.

Authors:  L Wang; B Munch-Petersen; A Herrström Sjöberg; U Hellman; T Bergman; H Jörnvall; S Eriksson
Journal:  FEBS Lett       Date:  1999-01-25       Impact factor: 4.124

7.  Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Authors:  Sherifa Hasabelnaby; Ayman Goudah; Hitesh K Agarwal; Mosaad S M abd Alla; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-07-27       Impact factor: 6.514

8.  Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy.

Authors:  Ashraf S Al-Madhoun; Jayaseharan Johnsamuel; Rolf F Barth; Werner Tjarks; Staffan Eriksson
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

9.  Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.

Authors:  Rolf F Barth; Weilian Yang; Ashraf S Al-Madhoun; Jayaseharan Johnsamuel; Youngjoo Byun; Subhash Chandra; Duane R Smith; Werner Tjarks; Staffan Eriksson
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

10.  Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.

Authors:  Kamel El Omari; Nicola Solaroli; Anna Karlsson; Jan Balzarini; David K Stammers
Journal:  BMC Struct Biol       Date:  2006-10-24
View more
  3 in total

1.  Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer.

Authors:  Hitesh K Agarwal; Ahmed Khalil; Keisuke Ishita; Weilian Yang; Robin J Nakkula; Lai-Chu Wu; Tehane Ali; Rohit Tiwari; Youngjoo Byun; Rolf F Barth; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2015-05-27       Impact factor: 6.514

2.  Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors.

Authors:  Rolf F Barth; Weilian Yang; Robin J Nakkula; Youngjoo Byun; Werner Tjarks; Lai Chu Wu; Peter J Binns; Kent J Riley
Journal:  Appl Radiat Isot       Date:  2015-07-02       Impact factor: 1.513

Review 3.  N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Werner Tjarks
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.